Ovarian Cancer

Treatment with the folate receptor α–directed antibody-drug conjugate luveltamab tazevibulin led to a 37.5% overall response rate in Frα-selected patients with advanced ovarian cancer, defined by a tumor proportion score above 25%.

The FDA has granted a breakthrough device designation to the OverC Multi-Cancer Detection Blood Test for the early detection of cancers including esophageal, liver, lung, ovarian, and pancreatic in adults aged to 50 to 75 years with average risk.

Peter Dottino, MD, FACOG, discusses the need for more accurate early screening tests for ovarian cancer, why testing for early-stage endometrial cancer is also important, the process used to develop the screening test, and how it could be implemented into practice if it is approved by the FDA.

During his career, David M. Gershenson, MD, has helped turn ovarian cancer treatment into an evidence-based field and built better therapies through an improved biological understanding of the disease.

Caroline Billingsley, MD, discusses the effect of mirvetuximab soravtansine’s approval on the treatment landscape in ovarian cancer and avenues for future research with antibody-drug conjugates and immunotherapy in this space.

Bobbie J. Rimel, MD, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.

The use of an individualized starting dose of niraparib led to a trend toward improved overall survival as maintenance therapy vs placebo in Chinese patients with platinum-sensitive, recurrent ovarian cancer regardless of germline BRCA mutation status, according to data from the phase 3 NORA trial.

Rodney Rocconi, MD, discusses the impact of the phase 3 SORAYA trial in folate receptor alpha–positive ovarian cancer.

Olaparib plus durvalumab and bevacizumab led to prolonged survival and disease control without causing additive toxicity in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer.

Increasing the duration of bevacizumab treatment in the frontline setting did not improve progression-free survival for patients with advanced ovarian cancer.

The FDA has asked Clovis Oncology to limit use of rucaparib to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.

The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.

Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.

The FDA has approved the VENTANA FOLR1 RxDx assay, the first immunohistochemistry companion diagnostic test to help identify patients with epithelial ovarian cancer who are eligible for treatment with mirvetuximab soravtansine-gynx.

The FDA has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment of select patients with folate receptor α–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

At the request of the FDA, GlaxoSmithKline plc will restrict the second-line maintenance indication for niraparib to only the population of patients with recurrent ovarian cancer whose tumors harbor deleterious or suspected deleterious germline BRCA mutations.

A core component of any type of therapeutic research is to enhance clinical benefit.

The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.

A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.

Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.

Kathleen N. Moore, MD, MS, discusses the clinical implications of the potential FDA approval of mirvetuximab soravtansine, observations from other antibody-drug conjugates under investigation in clinical trials, and the rationale of examining PARP inhibitor–based combinations in ovarian cancer.

Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.

Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.

Bobbie J. Rimel, MD, discusses how PARP inhibitors are deployed across different treatment settings of ovarian cancer, the recent market withdrawal of PARP inhibitors in later-line indications, and ongoing research efforts at Cedars-Sinai Medical Center for patients with ovarian cancer.

Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.